Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,011.04 -11.17 (-0.22%) Dow
37,761.91 +8.60 (+0.02%) Nasdaq
15,611.45 -71.92 (-0.46%) Bitcoin USD
63,215.84 +1,392.02 (+2.25%) CMC Crypto 200
885.54 0.00 (0.00%)
GILD Jan 2025 82.500 put
| Previous close | 12.15 |
| Open | 12.15 |
| Bid | 11.10 |
| Ask | 12.10 |
| Strike | 82.50 |
| Expiry date | 2025-01-17 |
| Day's range | 12.15 - 12.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.19k |
ZacksAnalysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
ZacksXilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
